46 results about "Soma" patented technology

There is provided an improved neuron model for spiking neural networks. The neuron model comprises somatic synapses as well as dendritic synapses. The somatic synapses are used for receiving an input token, and the dendritic synapses are used for receiving contextual data. The contextual data is used to modulate the behavior of the spiking neuron. The neuron model may be used to implement an attention mechanism in SSNs and to implement a Mixture-of-Experts architecture.

The invention provides a marker of spinal cord functional neural precursor cells, a detection method and a sorting method, and belongs to the technical field of biological medicine. The invention provides application of a marker detection reagent in preparation of a kit for detecting spinal cord functional neural precursor cells. The invention further provides a sorting-based method for separating the SFNPCs cells, and the cells are sorted through the Marker of the specific SFNPCs, so that the cell purity of the SFNPCs is remarkably improved, the difference between batches is reduced, and a high-purity and homogeneous SFNPCs cell population is obtained. The survival rate of the SFNPCs cells separated and subcultured to the P9 generation by the method disclosed by the invention is more than 85%, and the SFNPCs cells have a good treatment effect on a spinal cord injury model.

The invention discloses a fruit image classification method based on a wide area network dendritic neuron model, and the method comprises the steps: achieving the multi-scale feature extraction through parallel 1 * 1, 3 * 3 and 5 * 5 convolution and pooling branches, carrying out the fusion convolution, LeCannTanh activation and batch normalization, generating a feature representation through the combination of global average pooling and a lightweight feedforward network, and carrying out the classification of fruit images through the feature representation. And self-adaptive nonlinear classification is realized by means of synaptic-dendritic-somatic cell-axon hierarchical processing of dynamic dendritic neurons. Experimental results show that the method has the advantages of high precision, high robustness and low time delay in scenes with complex backgrounds, large intra-class differences and small samples, and is suitable for industrial applications such as intelligent sorting and automatic quality inspection.

The present application relates to a nutritional composition, a product comprising the same and use thereof in the preparation of a product for alleviating synaptic plasticity impairment of a body. The nutritional composition comprises: docosahexaenoic acid (DHA) and / or a metabolic precursor thereof, sodium hyaluronate (SH), and lactoferrin (LF). When docosahexaenoic acid (DHA), sodium hyaluronate (SH) and lactoferrin (LF) are used in combination, they can synergistically alleviate synaptic plasticity impairment of a body, in particular, increase nerve growth factor (NGF) content and / or brain-derived neurotrophic factor (BDNF) content in PC12 cells of the body, and / or increase expression of synaptic-related proteins in PC12 cells of the body.

A method for generating human midbrain immature neurons and mature dopaminergic neurons from neural progenitor cells is provided. The immature and mature midbrain neurons are obtained from neural progenitor cells such as committed midbrain neural stem cells (NSCs) and midbrain neural progenitor cells (midbrain NPCs), which are themselves generated from human pluripotent stem cells. The method for generating midbrain immature neurons and mature neurons uses a chemically defined medium that enables the generation of mature dopaminergic neurons in just 23 days. Media, isolated cell populations, and kits are also provided.

The application discloses an induction method for directional differentiation of neural stem cells into dopaminergic neurons, comprising the following steps: S1, activation and adhesion of NSCs; S2, directional induction of midbrain precursor cells; S3, directional induction of dopaminergic neurons; and S4, synaptic function maturation induction. The induction method for directional differentiation of neural stem cells into dopaminergic neurons can significantly improve the directional efficiency and lineage specificity of the midbrain precursor cells: by adding salvianolic acid B and icariin, and in cooperation with SHH, FGF8 and other induction factors, the midbrain lineage-specific signal pathway can be efficiently activated, the positive rate of the midbrain precursor cell marker LMX1A is increased to more than 76%, which is far better than 49% of the existing system, and abnormal differentiation of non-midbrain lineages is effectively inhibited.

Provided is the use of a population of nerve cells comprising forebrain nerve precursor cells (FNPCs) having specific developmental characteristics in the treatment of a nerve injury disease, a neurodegenerative disease, a neurodevelopmental disease, or other conditions associated with death and / or insufficiency of forebrain nerve cells, in particular in the treatment of a disease associated with death and / or insufficiency of the nerve cells of the nerve cells of the nerve cells of the nerve cell of the nerve cell of the nerve cell of the nerve cell of the nerve cell of the nerve cell of the nerve cell of the nerve cell of the nerve cell of the nerve cell of the nerve cell of the nerve cell of the nerve cell of the nerve cell of the nerve cell of the nerve cell of the nerve cell. Preferably, the forebrain nerve precursor cells with specific developmental characteristics highly express markers including FOXG1, PAX6 and NESTIN. Preferably, the population of nerve cells is obtained by culturing human pluripotent stem cells (hPSCs).

Provided are cortical interneurons and other neuronal cells and in vitro methods for producing such cortical interneurons and other neuronal cells by the directed differentiation of stem cells and neuronal progenitor cells. The present disclosure relates to novel methods of in vitro differentiation of stem cells and neural progenitor cells to produce several type neuronal cells and their precursor cells, including cortical interneurons, hypothalamic neurons and pre-optic cholinergic neurons. The present disclosure describes the derivation of these cells via inhibiting SMAD and Wnt signaling pathways and activating SHH signaling pathway. The present disclosure relates to the novel discovery that the timing and duration of SHH activation can be harnessed to direct controlled differentiation of neural progenitor cells into either cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons. The present disclosure also relates to compositions of cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons, and their precursors, that are highly enriched and can be used in variety of application. These cells can be used therapeutically to treat neurodegenerative and neuropsychiatric disorders, and can be used for disease modeling and drug screening.

The invention belongs to the field of biomedical materials, and particularly relates to a hydrogel composite scaffold loaded with human spinal cord V3 precursor cells for spinal cord injury repair and a preparation method of the hydrogel composite scaffold. The hydrogel composite scaffold comprises hydrogel and human spinal cord V3 neural precursor cells, hydrogel is used as a carrier, the human spinal cord V3 neural precursor cells are loaded on the hydrogel, and the hydrogel is formed by oxidized hyaluronic acid and carboxymethyl chitosan through a Schiff base cross-linking reaction. The specific preparation method comprises the following steps: mixing the human spinal cord V3 neural precursor cells with hydrogel to obtain the hydrogel composite scaffold loaded with the human spinal cord V3 neural precursor cells. Therefore, the technical problems of low cell survival rate, non-uniform cell distribution and difficulty in controlling the cell differentiation direction in spinal cord injury repair in the prior art are solved.

Methods for identifying, isolating and enriching neural stem and progenitor cells (NSPC) such as ventricular radial glia, outer radial glia, astrocytes, pre-oligodendrocyte precursor cells, oligodendrocyte precursor cells, oligodendrocytes, early excitatory neurons, late excitatory neurons, bipotent glial progenitors, and inhibitory neurons are provided. These methods find use in transplantation, to eliminate specific cell subsets, for experimental evaluation, as a source of lineage and cell-specific products, and the like, for example for use in treating human disorders of the central nervous system (CNS).

The present invention relates to a method of generating an in vitro modular 3D brain tissue model (3D BTM) comprising: a. mixing 50,000 to 1,000,000 freshly splitted, single neurons (NE) and astrocytes (AS) or their precursor cells in a ratio of NE:AS = 1:3 to 10:1, followed by spinning down to introduce self-aggregation in low attachment conditions, without addition of exogenous matrices; b. treating cells obtained in step a. with a NOTCH signaling inhibitor for driving terminal neuron differentiation for at least 2 days; c. treating the cells obtained in step b. with at least one mitotic inhibitor to remove residual dividing cells for at least 3 days, thereby yielding a post-mitotic aggregated 3D culture of neurons and astrocytes; d. adding differentiated microglia (MG) to the culture obtained in step c. in a ratio of NE:MG = 1:1 to 20:1, to initiate migration of MG into the culture for 3-10 days; e. culturing the culture obtained in step d. in neuron media with addition of TGFβ1 and cytokines selected from the group comprising CSF1-R agonists to support microglia maintenance and proliferation for at least 2 weeks, thereby inducing formation of a modular in vitro 3D BTM culture.

The invention belongs to the technical field of medicines, and provides application of polypeptide in preparation of a medicine for treating cerebral apoplexy. The amino acid sequence of the polypeptide is as follows: Ala-Glu-Pro-Val-Pro-Leu. The polypeptide has different degrees of significant improvement effects on death rate, neurobehavioral scoring and cerebral infarction volume of model rats, can significantly improve rat brain tissue hippocampal CA1 region vertebral cell injury, and also has significant improvement effects on brain microcirculation after bilateral carotid artery ligation of the model rats.

The present application relates to the field of medical biotechnology, and provides a dopaminergic neuron precursor cell surface marker F3 and / or SSTR2, and high-purity dopaminergic neuron precursor cells are obtained by screening the dopaminergic neuron precursor cells using the marker, and the dopaminergic neuron precursor cells have a higher efficiency of differentiating into dopaminergic neurons.

Somatic instability (SI) in the mutant HTT allele is a high value therapeutic target for Huntington's Disease (HD). However, rates of SI and the speed of HD progression vary widely with inherited germline CAG repeat lengths across the HD patient population. Understanding this variability and projecting the treatable range of patients for SI-directed therapies is important to their design, preclinical development, and conferring optimal benefit to HD patients. A computational model and related method(s) track the percentage of healthy medium spiny neurons (MSNs) across the lifetime of HD patients. Changes in MSN survival are predicted based on an exemplary SI-directed interventional gene therapy. The range of treatable patients is also projected. The flexible framework provided by the computational model and related method(s) enables therapeutic performance prediction and projecting outcomes across the HD patient population and furthermore, serves as a valuable tool for defining the target populations for SI-directed therapies.

Disclosed herein are methods for generating dopaminergic neurons and organoids comprising thereof. Particularly, the disclosure relates to methods for generating dopaminergic neurons by differentiating stem or precursor cells into Achaete-scute family bHLH transcription factor 1 (Ascl1)-driven mesenchymal progenitor cells and then terminally differentiating the Ascl1-driven mesenchymal progenitor cells into dopaminergic neurons alone or alongside astrocyte and hematopoietic precursor cells.

1. The name of this design product: Neuroelectrophysiological detection and stimulation platform. 2. Purpose of this product design: This product design is used for neuroelectrophysiological detection and stimulation of isolated cells and can be used in conjunction with an inverted microscope. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: Stereoscopic drawing 1.

The invention belongs to the technical field of biological medicine and neuroscience. Specifically, the present invention provides a cellular formulation for the treatment of Parkinson's disease comprising midbrain dopaminergic nerve precursor cells and a physiologically compatible solution wherein the cellular formulation is formulated as an injectable formulation for administration against the parathalamic nucleus (PF) region. The present invention also provides a method of treating Parkinson's disease comprising administering midbrain dopaminergic nerve precursor cells to a parathalamic nucleus (PF) region of a subject in need thereof.

The present disclosure provides methods of generating neural precursor cells having glial preference from induced pluripotent cells and further differentiating the neural precursor cells into astrocytes. Further provided herein are methods of screening assays using astrocytes, models that mimic the human brain, and cell therapies.

The invention belongs to the technical field of stem cell culture, and discloses a construction method and application for inducing and differentiating intestinal neural crest cells into colloidal precursor cells, the construction method comprises the following steps: S11, culturing the intestinal neural crest cells for 4 days to form neurospheres, sucking out supernatant containing the suspended neurospheres, centrifuging, discarding the supernatant, digesting with pancreatin, and collecting the supernatant; adding a DMEM / F12 culture medium to stop digestion, centrifuging, and discarding supernatant; s12, resuspending the neural spheres by using a colloidal precursor cell induction culture medium, inoculating the neural spheres into a cell culture bottle, and culturing in an incubator containing 5% of CO2 at 37 DEG C; and S13, after culturing for 16 hours, taking out the cells from the incubator to obtain the colloidal precursor cells. According to the method disclosed by the invention, intestinal neural crest cells are induced and differentiated into glial precursor cells and are further induced and differentiated into neurons, tool cells are provided for treatment of enteric nervous system diseases, a new tool is provided for understanding development and diseases of an enteric nervous system, and meanwhile, possibility is provided for developing a new treatment method.

The invention relates to a liquid dressing for skin and a preparation method of the liquid dressing. A film forming material of the liquid dressing comprises glial cell supernate. The neuroglial cells used in the invention are derived from neural stem cells which have been subjected to long-term in-vitro culture amplification, so that the obtained culture supernatant has the advantages of large scale, stable quality and mature technology, and a large number of liquid dressing products with stable and consistent quality standards can be provided in a short time; meanwhile, the supernate has good film-forming property and safety, contains a large number of human cell active components which are good in human body compatibility and beneficial to wound healing, and is suitable for large-scale batch production and application.

The invention relates to products and methods for transdifferentiating oligodendrocytes and / or oligodendrocyte precursor cells to neurons. The invention further relates to methods of treating central nervous system disorders and conditions.

The invention relates to products and methods for transdifferentiating oligodendrocytes and / or oligodendrocyte precursor cells to neurons. The invention further relates to methods of treating central nervous system disorders and conditions.

The invention relates to the technical field of biology, in particular to a medicine and application thereof. The drug is an exosome (DPSCs-Exos) derived from dental pulp stem cells (DPSCs-Exos). The DPSCs-Exos is given after acute cerebral apoplexy, so that sensory movement and cognitive function recovery after cerebral ischemia can be promoted. The DPSCs-Exos can improve ischemia for 45 minutes, and brain tissue injury and neurological function injury of animals after reperfusion for 28 days. The DPSCs-Exos promotes the expression increase of protein arginine methyltransferase (PRMT5) in oligodendroglia precursor cells (OPC), inhibits the expression of a differentiation inhibition factor 2 (ID2) through nucleation, promotes the OPCs to proliferate and differentiate into oligodendroglia cells (OL), and promotes the integrity repair of white matter. In addition, DPSCs-Exos can promote proliferation and migration of vascular endothelial cells and promote blood brain barrier repair.

The present invention relates to use of slow-releasing hydrogen sulfide organic donor ADT-OH drugs in the differentiation of neural precursor cells. ADT-OH can induce more directed differentiation of neural precursor cells into neurons and oligodendrocytes and less differentiation into astrocytes, promote the axon growth of neurons, and reduce the death of neural precursor cells, thereby providing a direction for the transplantation of neural precursor cells to repair damaged nerves. ADT-OH will likely become a new drug target for the clinical treatment of nervous system diseases.

Disclosed is a composition for supporting survival and differentiation of neural precursor cells (NPCs) grafted into a neurological injury or disease site, the composition comprising: (a) a gel forming molecule; and (b) a chemokine receptor type 5 (CCR5) antagonist. Also disclosed is a method of treating a neurological injury or disease of a subject, comprising (a) mixing NPCs with the composition as disclosed herein; and (b) administering a mixture of the NPCs and the composition into a neurological injury or disease site of the subject, to thereby support survival and differentiation of the NPCs. Also disclosed is use of a mixture of NPCs and the composition as disclosed herein in the manufacture of a medicament for treating a neurological injury or disease of a subject, wherein the mixture is to be administered into a neurological injury or disease site of the subject, to thereby support survival and differentiation of the NPCs. Further disclosed is a kit for use in supporting survival and differentiation of NPCs grafted into a neurological injury or disease site, the kit comprising: (a) the composition as disclosed herein; (b) artificial cerebral spinal fluid (a-CSF); (c) CaCl2; and (d) thrombin.

The invention relates to products and methods for transdifferentiating oligodendrocytes and / or oligodendrocyte precursor cells to neurons. The invention further relates to methods of treating central nervous system disorders and conditions.

The present invention provides a use of overexpressing the SMAD3 gene in inducing the reprogramming of human cells into functional neurons. Under the condition of overexpressing a single gene SMAD3, neuron cells with a TUJ1 positive rate of 60% can be obtained in only about 5 days of induction time. The induction time is greatly shortened and the induction efficiency is greatly improved.

The invention provides an in-vitro cerebral cortex intermediate neuron precursor cell population as well as a preparation method and application of the in-vitro cerebral cortex intermediate neuron precursor cell population. According to the cell population, the iNSC is taken as an initial cell to directionally differentiate to the neuroectoderm cell, so that neuroendoderm and neuromesoderm impurity cells generated in the differentiation process can be reduced, the cell differentiation direction is more accurate, and the differentiated cell purity is higher. The cell population can be used for the prevention, diagnosis and treatment of nervous system diseases.

The present disclosure provides methods for generating glial-biased neural progenitor cells from induced pluripotent cells and further differentiating the neural progenitor cells into astrocytes. Further provided herein are methods for using astrocytes in screening assays, models that mimic the human brain, and cell therapy.

The present disclosure provides a flexible biodegradable and resorbable brain (or other tissue) stimulation electrode for temporally regulated neuromodulation of neural precursor cells (NPCs), which may also be used for recording electrical signals in the brain or other tissue. Using the cathodally skewed electrochemical window of molybdenum and the volumetric charge transfer properties of a conductive polymer, the electrodes are designed with high charge injection capacity for the delivery of biphasic monopolar stimulation. These electrodes are biocompatible and can deliver an electric field sufficient for NPC activation for at least 7 days post implantation before undergoing resorption in physiological conditions., thereby eliminating the need for surgical extraction. The biodegradable electrode demonstrated its potential to be used for NPC based neural repair strategies.